Determinants of antipsychotic response in schizophrenia: Implications for practice and future clinical trials

Journal of Clinical Psychiatry

Volumn 75, Issue 4, 2014, Pages

  Rabinowitz, Jonathan ^a   Werbeloff, Nomi ^a   Caers, Ivo ^b   Mandel, Francine S ^c   Stauffer, Virginia ^d   Ménard, François ^e   Kinon, Bruce J ^d   Kapur, Shiti ^f  

^a BAR ILAN UNIVERSITY   (Israel)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c PFIZER INC   (United States)

^d Eli Lffly   (United States)

^e Lundbeck   (France)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL (TOPIC); DISEASE DURATION; DRUG RESPONSE; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; ONSET AGE; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE; STUDY DESIGN; SYMPTOM ASSESSMENT; TREATMENT DURATION; VALIDATION STUDY; YOUNG ADULT;

ADULT; AGE FACTORS; AGE OF ONSET; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; FEMALE; HOSPITALIZATION; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SEX FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899706249     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13m08853     Document Type: Article

References (22)

1. Meltzer HY, Rabinowitz J, Lee MA, et al. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Am J Psychiatry. 1997;154(4):475-482.
2. Hollis C. Adult outcomes of child and adolescent onset schizophrenia: Diagnostic stability and predictive validity. Am I Psychiatry. 2000;157(1O):1652-1659.
3. Szymanski S, Lieberman JA, Alvir JM, et al. Gender differences in onset of illness, treatment response, course, and biologic indexes in first episode schizophrenic patients. Am J Psychiatry. 1995;152(5):698-703.
4. Goldberg SC, Schooler NR, Davidson EM, et al. Sex and race differences in response to drug treatment among schizophrenics. Psychopharmacologia. 1966;9(1):31-47.
5. Rubinow DR, Moore M. Sex dependent modulation of treatment response. Dialogues din Neurosci. 2004;6(1):39-51.
6. Lieberman JA. Is schizophrenia a neurodegenerative disorder? a clinical and neurobiological perspective. Biol Psychiatry. 1999;46(6):729-739.
7. Chen YF, Wang SJ, Khin NA, et al. Trial design issues and treatment effect modeling in multi regional schizophrenia trials. Pharni Stat. 2010;9(3):217-229.
8. Khin NA, Chen YF, Yang Y, et al. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration. I din Psychiatry. 2012;73(6):856-864.
9. Volz A, Khorsand ?4 Gillies D, et al. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev. 2007;(1 ):CD006391.
10. Rabinowitz J, Levine SZ, Barkai 0, et al. Dropout rates in randomized clinical trials of antipsychotics: A meta analysis comparing first and second generation drugs and an examination of the role of trial design features. Schizophr Bull. 2009;35(4) :775-788.
11. EMEA reflection paper on the extrapolation of results from clinical studies conducted outside Europe to the EU population. EMEA/CHMP/ EWP/692702. London, UK: European Medicines Agency; 2009. http://www. ema.europa.eu/docs/en- GB/document-library/Scientific-guideline/2009/1-1/ WC50001346X.pdf. Accessed January 31,2014.
12. Leucht S, Arbter D, Engel RR, et al. How effective are second generation antipsychotic drugs? a meta analysis of placebo controlled trials. Mol Psychiatry. 2009;14(4):429-447.
13. National Advisory Mental Health Council?s Workgroup. From discovery to cure: Accelerating the development of new and personalized interventions for mental illnesses. National Advisory Mental Health Council. Washington, DC: National Institutes of Health; 2010. http://www.nimh.nih.gov/about/advisory boards and groups/namhc/reports/fromdiscoverytocure.pdf. Accessed January 31,2014.
14. Agid 0, Kapur S, Arenovich T, et al. Delayed onset hypothesis of antipsychotic action: A hypothesis tested and rejected. Arch Gen Psychiatry. 2003;60(12):1228-1235.
15. Marques TR, Arenovich T, Agid 0, et al. The different trajectories of antipsychotic response: Antipsychotics versus placebo. Psychol Med. 2011;41(7):1481-1488.
16. Riley lID, Lambert PC, Abo Zaid G. Meta analysis of individual participant data: Rationale, conduct, and reporting. BMJ. 2010;340:c221.
17. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
18. Overall JE, Gorham DE. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10(3):799-812.
19. Kinon BJ, Noordsy DL, Liu Seifert H, et al. Randomized, double blind 6 month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. I din Psychopharniacol. 2006;26(5):453-461.
20. Merkle EC, Shaffer VA. Binary recursive partitioning: Background, methods, and application to psychology. BrJMath Stat Psychol. 2011;64(pt i):161 lxi.
21. Strobl C, Malley J, Tutz G. An introduction to recursive partitioning: Rationale, application, and characteristics of classification and regression trees, bagging, and random forests. Psychol Methods. 2009;14(4):323-348.
22. Faraone SV, Chen WJ, Goldstein JM, et al. Gender differences in age at onset of schizophrenia. Br I Psychiatry. 1994;164(5):625-629.